Hok Pang
About Hok Pang
Hok Pang is the Senior Director, WW Medical Oncology Markets Lead at Bristol Myers Squibb, based in Uxbridge, UK, with extensive experience in medical affairs across various therapeutic areas.
Current Position at Bristol Myers Squibb
Hok Pang is the Senior Director, WW Medical Oncology Markets Lead at Bristol Myers Squibb in Uxbridge, UK. His role involves overseeing medical affairs and strategy for oncology markets on a global scale, contributing to the leadership team in shaping oncology treatment paradigms.
Previous Roles at Bristol Myers Squibb
Hok Pang has a rich history at Bristol Myers Squibb, serving in various leadership roles. From 2019 to 2021, he was the WW Oncology Medical Lead (Major Markets). Prior to this, he held the position of HQ Oncology Medical Lead for the European Markets, Australia, and Canada Region from 2018 to 2019. He also served as Medical Lead - Oncology for the UK & Ireland from 2017 to 2018 and as Medical Lead - Haemato-Oncology for the UK & Ireland from 2015 to 2017.
Experience in Novartis
Before joining Bristol Myers Squibb, Hok Pang worked at Novartis as the Medical Lead - Chronic Myeloid Leukaemia (Haematology), UK, from 2013 to 2015. His role focused on medical leadership in haematology, specifically chronic myeloid leukaemia, which added to his expertise in oncology and haematology.
Roles at Roche Pharmaceuticals
Hok Pang's tenure at Roche Pharmaceuticals spanned several roles. He served as Associate Head of Medical Affairs - Inflammation/Immunology & Ophthalmology from 2011 to 2013 and as Senior Medical Manager, Rheumatology from 2009 to 2011. His earlier role at Roche was as a Medical Manager, Anaemia/Nephrology from 2008 to 2009, showcasing his versatility across multiple therapeutic areas.
Experience at Otsuka Pharmaceuticals
Hok Pang's career also includes a role at Otsuka Pharmaceuticals (UK) Ltd, where he served as Medical Manager, UK, from 2007 to 2008. His work at Otsuka marked the beginning of his long-standing career in medical management within the pharmaceutical industry.